Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

41. Daily and cyclic parathyroid hormone in women receiving alendronate. Full Text available with Trip Pro

Daily and cyclic parathyroid hormone in women receiving alendronate. We evaluated whether patients with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treatment and whether short, three-month cycles of parathyroid hormone therapy could be as effective as daily administration.We randomly assigned 126 women with osteoporosis who had been taking alendronate for at least 1 year to continued alendronate plus parathyroid hormone (1-34) subcutaneously daily (...) , continued alendronate plus parathyroid hormone (1-34) subcutaneously daily for three 3-month cycles alternating with 3-month periods without parathyroid hormone, or alendronate alone for 15 months.In both parathyroid hormone groups, bone formation indexes rose swiftly. Among the women who were receiving cyclic parathyroid hormone, bone formation declined during cycles without parathyroid hormone and increased again during cycles with parathyroid hormone. Bone resorption increased in both parathyroid

2005 NEJM Controlled trial quality: uncertain

42. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Bisphosphonates (...) (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Bisphosphonates

2005 Health Technology Assessment (HTA) Database.

43. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment (...) of postmenopausal osteoporosis Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention

2005 Health Technology Assessment (HTA) Database.

44. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

45. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Schousboe J T, Nyman J A, Kane R L, Ensrud K E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined 5-year treatment with alendronate in postmenopausal women with osteopenia. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of postmenopausal women with osteopenia, aged 55 to 75 years, and with a bone mineral density (BMD) T-score between -2.4 and -1.5. Setting The setting

2005 NHS Economic Evaluation Database.

46. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women

of osteoporosis. Osteoporos Int 2002;13:841-57. Johnell O, Jonsson B, Jonsson L, et al. Cost-effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003;21:305-14. Iglesias CP, Torgerson DJ, Bearne A, et al. The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002;95:305-11. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment (...) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Schousboe J T, Ensrud K E, Nyman J

2005 NHS Economic Evaluation Database.

47. Ten years' experience with alendronate for osteoporosis in postmenopausal women. Full Text available with Trip Pro

Ten years' experience with alendronate for osteoporosis in postmenopausal women. Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years.The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received alendronate in years 4 and 5 and then were (...) discharged. Women in the original active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5). In two further extensions (years 6 and 7, and 8 through 10), women who had received 5 mg or 10 mg of alendronate daily continued on the same treatment. Women in the discontinuation group received 20 mg of alendronate daily for two years and 5 mg daily in years 3, 4, and 5, followed by five years of placebo. Randomized group assignments and blinding were maintained

2004 NEJM Controlled trial quality: uncertain

48. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. Full Text available with Trip Pro

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. Osteoporosis is a well-known complication of cardiac transplantation. We conducted a randomized trial comparing alendronate with calcitriol for the prevention of bone loss during the first year after cardiac transplantation.A total of 149 patients were randomly assigned to receive either alendronate (10 mg per day) or calcitriol (0.5 microg per day) a mean (+/-SD) of 21+/-11 days after transplantation (...) . Estimates of bone loss and the incidence of fractures among untreated patients were obtained from a reference group of 27 prospectively recruited patients who received cardiac transplants within the same period as the intervention groups.At one year, the bone mineral density at the lumbar spine had decreased by a mean of 0.7 percent in the alendronate group and 1.6 percent in the calcitriol group (P=0.25 for the test of no difference). The bone mineral density at the femoral neck decreased by a mean

2004 NEJM Controlled trial quality: uncertain

49. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study

Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Kane S, Borisov N N, Brixner D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate (5 or 10 mg/day, or 35 or 70 mg/week) and risedronate (5 mg/day), two commonly prescribed oral bisphosphonates used to treat postmenopausal and glucocorticoid-induced osteoporosis, was examined. Type

2004 NHS Economic Evaluation Database.

50. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Full Text available with Trip Pro

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone.A total of 238 (...) postmenopausal women (who were not using bisphosphonates) with low bone mineral density at the hip or spine (a T score of less than -2.5, or a T score of less than -2.0 with an additional risk factor for osteoporosis) were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months. Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative

2003 NEJM Controlled trial quality: uncertain

51. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. (Abstract)

The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density.We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 microg subcutaneously daily; 27 men), or both (28 men (...) ). Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6. The bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured every six months with the use of dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured at base line and month 30 by means of quantitative computed tomography. Serum alkaline phosphatase levels were measured every six months. The primary end point was the rate

2003 NEJM Controlled trial quality: uncertain

52. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Full Text available with Trip Pro

alendronate sodium in combination are efficacious and safe, and how they compare with monotherapy in community-dwelling elderly women.Randomized, double-blind, placebo-controlled, clinical trial.Five hundred seventy-three community-dwelling women age 65 years or older were screened: 485 completed screening and 373 (aged 65 to 90 years) were randomized following a 3-month, open-label, run-in phase with hormone replacement and alendronate placebo. The trial was conducted at a single academic US medical (...) Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Therapy with individual antiresorptive agents has been shown to be effective for prevention and treatment of postmenopausal osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates is safe or efficacious or how these agents compare in elderly women is unknown.To determine whether hormone replacement and the bisphosphonate

2003 JAMA Controlled trial quality: predicted high

53. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) hydrochloride, an agent within the class of drugs called selective oestrogen receptor modulators; and alendronate, a bisphosphonate. In all cases, the prescription drug interventions included calcium and vitamin D supplements. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The base-case study population included women who had not had a hysterectomy and who initiated therapy at age 55 years. They had a normal distribution of age-related baseline

2003 NHS Economic Evaluation Database.

54. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial

The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial Chrischilles E A, Dasbach E J, Rubenstein L M, Cook J R, Tabor H K, Black D M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate in the prevention of osteoporotic fractures. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised postmenopausal women with low bone mineral density (BMD

2001 NHS Economic Evaluation Database.

55. Alendronate for the treatment of osteoporosis in men. (Abstract)

Alendronate for the treatment of osteoporosis in men. Despite its association with disability, death, and increased medical costs, osteoporosis in men has been relatively neglected as a subject of study. There have been no large, controlled trials of treatment in men.In a two-year double-blind trial, we studied the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men (age, 31 to 87 years; mean, 63) with osteoporosis. Approximately one third had low serum (...) free testosterone concentrations at base line; the rest had normal concentrations. Men with other secondary causes of osteoporosis were excluded. All the men received calcium and vitamin D supplements. The main outcome measures were the percent changes in lumbar-spine, hip, and total-body bone mineral density.The men who received alendronate had a mean (+/-SE) increase in bone mineral density of 7.1+/-0.3 percent at the lumbar spine, 2.5+/-0.4 percent at the femoral neck, and 2.0+/-0.2 percent

2000 NEJM Controlled trial quality: uncertain

56. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. (Abstract)

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures.To test the hypothesis that 4 years of alendronate would decrease the risk of clinical and vertebral fractures in women who have low bone mineral density (BMD (...) and 250 IU of cholecalciferol. Subjects were randomly assigned to either placebo or 5 mg/d of alendronate sodium for 2 years followed by 10 mg/d for the remainder of the trial.Clinical fractures confirmed by x-ray reports, new vertebral deformities detected by morphometric measurements on radiographs, and BMD measured by dual x-ray absorptiometry.Alendronate increased BMD at all sites studied (P<.001) and reduced clinical fractures from 312 in the placebo group to 272 in the intervention group

1999 JAMA Controlled trial quality: predicted high

57. [Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures]

[Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures] Analisis coste-efectividad de alendronato frente a placebo en la prevencion de fractura de cadera [Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures] Analisis coste-efectividad de alendronato frente a placebo en la prevencion de fractura de cadera [Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures] Rodriguez Escolar C (...) , Fidalgo Garcia M L, Rubio Cebrian S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an alendronate-based therapy to prevent the risk of hip fracture in women with osteoporosis. The therapy consisted of 10 mg/day

1999 NHS Economic Evaluation Database.

58. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. (Abstract)

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear.We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo (...) at all measured sites, whereas the women treated with 5 mg of alendronate daily had a mean (+/-SE) increase in bone mineral density of 3.5+/-0.2 percent at the lumbar spine, 1.9+/-0.1 percent at the hip, and 0.7+/-0.1 percent for the total body (all P<0.001). Women treated with 2.5 mg of alendronate daily had smaller increases in bone mineral density. Alendronate did not increase bone mineral density of the forearm, but it slowed the loss. The responses to estrogen-progestin were 1 to 2 percentage

1998 NEJM Controlled trial quality: uncertain

59. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. (Abstract)

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment.We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point (...) was the difference in the mean percent change in lumbar-spine bone density from base line to week 48 between the groups. Secondary outcomes included changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures.The mean (+/-SE) bone density of the lumbar spine increased by 2.1+/-0.3 percent and 2.9+/-0.3 percent, respectively, in the groups that received 5 and 10 mg of alendronate per day (P<0.001) and decreased by 0.4+/-0.3 percent in the placebo group

1998 NEJM Controlled trial quality: predicted high

60. Bisphosphonates (alendronate and etidronate) in the management of osteoporosis

Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Best L, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Best L, Milne R. Bisphosphonates (...) (alendronate and etidronate) in the management of osteoporosis. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998 Authors' objectives The authors examine whether alendronate and etidronate should be used in the treatment of diagnosed osteoporosis. Authors' conclusions The authors find that the choice of target population is critical to the cost-utility of bisphosphonate treatment. If treatment is targeted towards individuals at high risk of fracture then both alendronate

1998 Health Technology Assessment (HTA) Database.